|
V.M. Moiseenko (1), F.V. Moiseenko (1, 2, 3), N.M. Volkov (1), G.A. Yanus (2), E.Sh. Kuligina (2), A.P. Sokolenko (2), S.N. Aleksakhina (2), V.A. Chubenko (1), K.S. Kozyreva (2), N.Kh. Abduloeva (1), M.M. Kramchaninov (1), A.S. Zhuravlev (1), V.A. Khinshtein (1), K.V. Shelekhova (1), A.A. Kudryavtsev (1), A.V. Myslik (1), A.O. Ivantsov (2), A.R. Venina (2), E.V. Preobrazhenskaya (2, 4), N.V. Mityushkina (2), A.G. Ievleva (2, 4), E.N. Imyanitov (2, 4)
Prospective II phase study on the evaluation of the efficacy of monotherapy with cetuximab as the first-line treatment for patients with metastatic colorectal cancer with wild-type KRas, NRas, and BRAF genes
|
№7 / 2018
|
Русский
